血液培养检测市场：区域、范围和预测

血液培养检测的市场规模及预测

预计2024年血液培养检测市场价值约为53.9亿美元，到2031年将达到99.7亿美元，2024年至2031年的复合年增长率约为8.81%。血液培养是一种诊断程序，用于检测血液中是否存在细菌、真菌和其他微生物，这可能表明存在全身性感染，如菌血症或败血症。当患者出现严重感染的迹象，例如发烧、发冷、心跳过快或精神错乱时，就会进行血液培养。血液培养对于诊断可能扩散至血液的感染至关重要。

血液培养测试对于治疗严重感染和确定治疗方案至关重要。血液培养有助于预防败血症等併发症，如果不及时治疗，可能会危及生命。

全球医疗保健支出的增加，加上医护人员和病患对传染病的认识提高，增加了对血液培养检测的需求。

全球血液培养检测市场动态

影响全球血液培养检测市场的关键市场动态

关键推动因素

血流感染发生率高：

血流感染发生率高：血流感染是全世界发病和死亡的主要原因。据估计，美国每年发生超过 60 万例血液感染，造成巨大的医疗费用。

对快速诊断技术的需求不断增加：

为了提供适当的抗生素治疗，越来越需要更快、更准确地诊断血流感染。这促使了先进的血液培养技术的开发和实施。

传染病发生率高：

败血症、肺炎和脑膜炎等传染病的全球负担不断增加。例如，2017年，败血症估计影响了全球4,890万人，并导致1,100万人死亡。

老年人口不断增加：

老年人的免疫系统较弱，更容易感染传染病。预计到 2050 年，全球 65 岁及以上人口将从 2020 年的 7.27 亿增加到 15 亿。

主要问题

解释的复杂性：

由于需要区分污染物和临床显着的病原体，因此血液培养结果的解释很困难。这种复杂性增加了对熟练专业人员的依赖，这可能会阻碍市场成长。调查发现，相当一部分实验室（79%）认为病原体鑑定对于准确解释很重要。

漫长的过程：

传统的血液培养测试通常需要几天才能提供结果，从而延迟诊断和治疗。美国的平均测试週转时间为两到三天，漫长的等待时间可能会对患者的治疗结果产生负面影响。

自动化系统成本高：

自动化血液培养系统所需的初始投资较高，从 50,000 美元到 100,000 美元不等，这使得小型医疗机构难以采用这些技术。

污染风险：

血液培养污染仍然是一个严重的问题，会导致假阳性结果，使诊断和治疗决策变得复杂。受污染的培养基会导致不必要的治疗并增加医疗成本。

主要趋势：

技术进步：

自动化血液培养系统的创新正在提高检测效率和准确性。由于检测技术的进步，自动化领域预计将以最快的速度成长。

传染病发生率增加：

医疗相关性感染呈上升趋势，美国大约每 31 名住院患者中就有 1 名感染。

增加医疗支出：

全球医疗保健支出的增加推动了先进诊断解决方案的采用，包括血液培养检测。这一趋势正在推动更有效的测试方法的开发和实施。

聚焦在败血症诊断：

血液培养检测在诊断败血症的重要性日益得到认可，在美国，每年约有 170 万人患有败血症，这进一步推动了市场需求。

目录

第 1 章全球血液培养检测市场简介

市场概况
• 研究范围
• 先决条件

第 2 章执行摘要

第 3 章：经过验证的市场研究方法

• 资料探勘
• 验证
• 主要来源
• 资料来源列表

第 4 章全球血液培养检测市场展望

• 概述
• 市场动态
  • 驱动程式
  • 阻碍因素
  • 机会
• 波特五力模型
• 价值链分析

第 5 章全球血液培养检测市场（依产品划分）

• 概述
• 装置
• 血培养基
• 检测试剂盒和试剂
• 血液培养配件

第6章 全球血液培养检测市场（依技术分类）

• 概述
• 聚合酶炼式反应 (PCR)
• 微阵列
• 基于文化的技术
• 蛋白质体学技术

第 7 章 全球血液培养检测市场（按应用）

• 概述
• 菌血症
• 真菌感染
• 分枝桿菌检测

第 8 章全球血液培养检测市场（按区域）

• 概述
• 北美洲
  • 美国
  • 加拿大
  • 墨西哥
• 欧洲
  • 德国
  • 英国
  • 法国
  • 其他欧洲国家
  亚太地区
  • 中国
  • 日本
  • 印度
  • 其他亚太地区
• 世界其他地区
  • 拉丁美洲
  • 中东和非洲

第 9 章全球血液培养检测市场的竞争格局

• 概述
• 各公司的市场排名
• 主要发展策略

第10章 公司简介

• Biomerieux SA
• Nanosphere, Inc.
• Becton, Dickinson and Company
• Roche Diagnostics
• Thermo Fisher Scientific, Inc.
• Bruker Corporation
• Cepheid（Danaher Corporation）

第 11 章附录

• 相关研究

Blood Culture Tests Market Size And Forecast

The Blood Culture Tests Market was valued at approximately USD 5.39 Billion in 2024 and is anticipated to reach USD 9.97 Billion by 2031, growing at a CAGR of about 8.81% from 2024 to 2031. A blood culture test is a diagnostic procedure used to detect the presence of bacteria, fungi, or other microorganisms in the bloodstream, which can indicate a systemic infection such as bacteremia or sepsis. Blood cultures are ordered when patients exhibit symptoms of severe infection, such as fever, chills, rapid heart rate, or confusion. They are crucial for diagnosing infections that may have spread to the bloodstream.

Blood culture tests are vital for managing serious infections and guiding treatment decisions. They help prevent complications such as sepsis, which can be life-threatening if not addressed promptly.

Growing worldwide healthcare expenditure, combined with improved knowledge of infectious diseases among healthcare providers and patients, has increased demand for blood culture testing.

Global Blood Culture Tests Market Dynamics

The key market dynamics that are shaping the global blood culture tests market include:

Key Drivers

High Incidence of Bloodstream Infections:

Bloodstream infections are a major cause of morbidity and mortality worldwide. In the United States, it is estimated that there are over 600,000 cases of bloodstream infections annually, resulting in significant healthcare costs.

Growing Demand for Rapid Diagnostic Techniques:

There is an increasing need for faster and more accurate diagnosis of bloodstream infections to guide appropriate antibiotic therapy. This has driven the development and adoption of advanced blood culture technologies.

High Prevalence of Infectious Diseases:

The global burden of infectious diseases, such as sepsis, pneumonia, and meningitis, has been rising. For example, in 2017, sepsis was estimated to affect 48.9 million people and result in 11 million deaths worldwide.

Rising Geriatric Population:

The elderly population is more susceptible to infections due to weakened immune systems. The global population aged 65 and above is projected to increase from 727 million in 2020 to 1.5 billion in 2050.

Key Challenges:

Complexity in Interpretation:

Interpreting blood culture results can be challenging due to the need to distinguish between contaminants and clinically significant pathogens. This complexity increases reliance on skilled professionals, which can hinder market growth. Studies indicate that a significant percentage of laboratories (79%) find organism identity crucial for accurate interpretation .

Time-Consuming Process:

Traditional blood culture tests often take several days to yield results, delaying diagnosis and treatment. This prolonged wait can negatively impact patient outcomes, as the average turnaround time in the U.S. is typically 2-3 days .

High Costs of Automated Systems:

The initial investment for automated blood culture systems can be substantial, ranging from $50,000 to $100,000, making it difficult for smaller healthcare facilities to adopt these technologies .

Contamination Risks:

Blood culture contamination remains a significant issue, leading to false-positive results that complicate diagnosis and treatment decisions. Contaminated cultures can result in unnecessary treatments and increased healthcare costs.

Key Trends:

Technological Advancements:

Innovations in automated blood culture systems are improving the efficiency and accuracy of tests. The automated segment is anticipated to grow at the fastest pace, driven by advancements in testing technology.

Rising Incidence of Infections:

The prevalence of healthcare-associated infections continues to rise, with approximately 1 in 31 hospitalized patients in the U.S. suffering from such infections, driving the demand for blood culture tests.

Increased Healthcare Expenditure:

Rising global healthcare expenditure is facilitating the adoption of advanced diagnostic solutions, including blood culture tests. This trend supports the development and implementation of more efficient testing methods.

Focus on Sepsis Diagnostics:

There is a growing recognition of the importance of blood culture tests in diagnosing sepsis, which affects approximately 1.7 million individuals annually in the U.S., further propelling market demand.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global Blood Culture Systems Market Regional Analysis

Here is a more detailed regional analysis of the global blood culture systems market:

North America:

North America accounted for 35% of the global blood culture tests market revenue in 2023, making it the largest market globally. This dominance is attributed to a well-established healthcare infrastructure and advanced diagnostic capabilities.

The region experiences a significant burden of bloodstream infections, with approximately 250,000 cases occurring annually in the U.S. alone. This high incidence drives demand for effective diagnostic tools like blood culture tests.

Technological Advancements: North America is at the forefront of technological innovations in blood culture testing, including automated systems that reduce turnaround times and improve accuracy. The presence of major players such as Becton, Dickinson and Company and bioMerieux enhances market growth through continuous product development.

Government-funded programs and initiatives aimed at improving infection control and management contribute to market growth. For example, funding from agencies like BARDA supports the development of advanced diagnostic technologies, which are crucial for timely infection diagnosis.

Asia Pacific

The Asia Pacific region is expected to exhibit the highest compound annual growth rate (CAGR) of 8.32% from 2023 to 2033, reflecting a significant demand for blood culture tests driven by increasing infection rates and healthcare advancements.

The region faces a growing incidence of bloodstream infections, including sepsis and hospital-associated infections. For instance, the World Health Organization estimates that around 49 million people suffer from sepsis globally each year, with a substantial number of cases occurring in Asia Pacific.

Countries like China and India are investing heavily in healthcare infrastructure and diagnostics, which enhances the capacity for early diagnosis and treatment of infectious diseases. This investment is crucial as the region aims to improve healthcare outcomes .

Increased awareness among healthcare professionals about the importance of accurate diagnosis of bloodstream infections is leading to greater acceptance and utilization of blood culture tests in clinical settings.

Global Blood Culture Systems Market: Segmentation Analysis

The Global Blood Culture Systems Market is Segmented on the Basis of Method, Product, Technology, Application, End-User And Geography.

Blood Culture Tests Market, By Method

• Conventional/Manual Methods
• Automated Methods

Based on Method, the market is segmented into Conventional/Manual Methods and Automated Methods. The conventional/manual methods dominate over automated methods. In 2023, conventional/manual blood culture methods held approximately 64.78% of the market share, making them the most widely used technique for blood culture testing. This dominance is attributed to their long-standing familiarity and acceptance among laboratory operators.

Blood Culture Tests Market, By Product

• Consumables
• Instruments
• Software & Services

Based on Product, the market is segmented into Consumables, Instruments and Software & Services. The consumables segment accounted for the largest share of the blood culture tests market in 2023, with a revenue of approximately USD 3.5 Billion. This segment includes essential items such as blood culture media, reagents, assay kits, and other supplies necessary for conducting blood culture tests.

Blood Culture Tests Market, By Technology

• Culture-based Technology
• Molecular Technologies
• Proteomics Technology

Based on Technology, the market is segmented into Culture-based Technology, Molecular Technologies and Proteomics Technology. The culture-based technology segment accounted for the largest share of the blood culture tests market in 2023, driven by its established effectiveness in detecting bacteria and fungi in blood samples. This segment remains the gold standard for diagnosing bloodstream infections.

Blood Culture Tests Market, By Application

• Bacteremia
• Fungemia
• Mycobacterial Detection

Based on Application, the market is segmented into Bacteremia, Fungemia and Mycobacterial Detection. The bacteremia segment holds the largest share of the blood culture tests market, primarily due to the high prevalence of bacterial infections in bloodstream cases. Bacteremia is a critical condition that requires prompt diagnosis and treatment, making blood culture tests essential.

Blood Culture Tests Market, By End-User

• Hospital Laboratories
• Reference Laboratories
• Academic Research Laboratories
• Other

Based on End-User, the market is segmented into Hospital Laboratories, Reference Laboratories, Academic Research Laboratories and Other. Hospital laboratories accounted for more than 45% of the blood culture tests market share in 2023. This significant share is due to the high volume of tests conducted in hospitals, particularly for patients with infectious diseases.

Blood Culture Tests Market, By Geography

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa
• On the basis of Geography, the market is classified into North America, Europe, Asia Pacific, and the Rest of the World. Hospital laboratories accounted for more than 45% of the blood culture tests market share in 2023. This significant share is due to the high volume of tests conducted in hospitals, particularly for patients with infectious diseases.

Key Players

• The "Global Blood Culture Tests Market" study report will provide valuable insight with an emphasis on the global market including some of the major players of the industry are
• Thermo Fisher Scientific, Inc., T2 Biosystems, Inc., Cepheid, Inc., Roche Diagnostics, Beckman Coulter, BioMerieux SA, IRIDICA, Bruker Corporation, Nanosphere, Inc., Becton Dickinson and Company, Abbott Laboratories, Siemens Healthineers AG, Streck, Omega Diagnostics Group PLC, Qiagen N.V., BD Diagnostics, & F. Hoffmann-La Roche Ltd, among others.

Our market analysis offers detailed information on major players wherein our analysts provide insight into the financial statements of all the major players, product portfolio, product benchmarking, and SWOT analysis. The competitive landscape section also includes market share analysis, key development strategies, recent developments, and market ranking analysis of the above-mentioned players globally.

• Blood Culture Tests Recent Developments
• In February 2023, Cepheid announced the launch of its new Xpert(R) Blood Culture Identification (BCID) test, which provides rapid identification of pathogens directly from positive blood cultures. This test significantly reduces the time required to identify infectious agents, enhancing the speed of diagnosis and treatment.
• In March 2023, Roche Diagnostics launched its new cobas(R) 8800 System for blood culture testing, which enhances the detection of pathogens in blood samples. This automated system is designed to provide faster results and improve workflow efficiency in clinical laboratories.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL BLOOD CULTURE TESTS MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL BLOOD CULTURE TESTS MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL BLOOD CULTURE TESTS MARKET, BY PRODUCT

• 5.1 Overview
• 5.2 Instruments
• 5.3 Blood Culture Media
• 5.4 Assay Kits & Reagents
• 5.5 Blood Culture Accessories

6 GLOBAL BLOOD CULTURE TESTS MARKET, BY TECHNOLOGY

• 6.1 Overview
• 6.2 Polymerase Chain Reaction (PCR)
• 6.3 Microarrays
• 6.4 Culture-Based Technology
• 6.5 Proteomics Technology

7 GLOBAL BLOOD CULTURE TESTS MARKET, BY APPLICATION

• 7.1 Overview
• 7.2 Bacteremia
• 7.3 Fungemia
• 7.4 Mycobacterial Detection

8 GLOBAL BLOOD CULTURE TESTS MARKET, BY GEOGRAPHY

• 8.1 Overview
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 U.K.
  • 8.3.3 France
  • 8.3.4 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Rest of Asia Pacific
• 8.5 Rest of the World
  • 8.5.1 Latin America
  • 8.5.2 Middle East And Africa

9 GLOBAL BLOOD CULTURE TESTS MARKET COMPETITIVE LANDSCAPE

• 9.1 Overview
• 9.2 Company Market Ranking
• 9.3 Key Development Strategies

10 COMPANY PROFILES

• 10.1 Biomerieux SA
  • 10.1.1 Overview
  • 10.1.2 Financial Performance
  • 10.1.3 Product Outlook
  • 10.1.4 Key Developments
• 10.2 Nanosphere, Inc.
  • 10.2.1 Overview
  • 10.2.2 Financial Performance
  • 10.2.3 Product Outlook
  • 10.2.4 Key Developments
• 10.3 Becton, Dickinson and Company
  • 10.3.1 Overview
  • 10.3.2 Financial Performance
  • 10.3.3 Product Outlook
  • 10.3.4 Key Developments
• 10.4 Roche Diagnostics
  • 10.4.1 Overview
  • 10.4.2 Financial Performance
  • 10.4.3 Product Outlook
  • 10.4.4 Key Developments
• 10.5 Thermo Fisher Scientific, Inc.
  • 10.5.1 Overview
  • 10.5.2 Financial Performance
  • 10.5.3 Product Outlook
  • 10.5.4 Key Developments
• 10.6 Bruker Corporation
  • 10.6.1 Overview
  • 10.6.2 Financial Performance
  • 10.6.3 Product Outlook
  • 10.6.4 Key Developments
• 10.7 Cepheid (Danaher Corporation)
  • 10.7.1 Overview
  • 10.7.2 Financial Performance
  • 10.7.3 Product Outlook
  • 10.7.4 Key Developments

11 Appendix

• 11.1 Related Research